Fresh Equities
ASX:1AD

ASX:1AD

ADALTA LIMITED

ADALTA LIMITED has not announced any current capital raises, but we are collecting interest for future raises.

Demand Registered for Next Raise
< $50k
Investors Interested in Next Raise
< 10
How Fresh Equities Works
Authentication

1. Create Account

Complete your onboarding digitally in less than 3 minutes.

Authentication

2. View Terms

View the full term sheet for the capital raise.

Authentication

3. Bid for Allocation

Submit and track your bid online.

Capital Raise History

Loading...


Company Overview

AdAlta is an innovative biotech company developing a unique range of new drug treatments. AdAlta has pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases. AdAlta is utilising the power of the i-body technology to create a pipeline of new drugs, with an initial focus on treating fibrotic diseases.

Type

Listed Company

GICS Sub-industry

Biotechnology

Head Office

15/2 Park Dr, Bundoora VIC 3086, Australia

Biotechnology
Health Care
Biotech
Biotech & Health

Price Chart


Quarterly Cash Flows

The numbers below are derived from quarterly cash flow reports provided by the company. Fresh Equities does not guarantee that the information provided is accurate, you can read the associated report by clicking read more for the quarter. Always do your own research and do not rely on the information provided here as your only source of research.

Loading...


Directors


Announcements

All
All Time
    AdAlta updated corporate presentation on 9 February 2020

    Periodic Reports

  • Appendix 4C - quarterly on 30 January 2020

    Commitments test entity quarterly reports

  • AdAlta Granted US Patent for AD-214 on 29 January 2020

    Progress Report

  • Appendix 3B on 20 January 2020

    Issued Capital

  • AD-214 Phase I strategy and timing update on 13 January 2020

    Progress Report

  • Final Director's Interest Notice on 2 January 2020

    Shareholder Details

    Director Resignation on 2 January 2020

    Company Administration

  • R&D Tax Incentive Facility on 19 December 2019

    Periodic Reports

  • Appendix 3B on 12 December 2019

    Issued Capital

  • AdAlta awarded Biomedical Translation Bridge Funding on 11 December 2019

    Periodic Reports

  • Load More

News

Fresh Equities does not have ADALTA LIMITED news data.